BACKGROUND AIMS: The present study investigates the influence of low-dose and short- term administration of corticosteroids and muscle relaxants on the muscular mass (MM) in hemiplegic ICU patients, with the aid of ultrasonography (U/S). METHODS:Thirty-seven patients hospitalised in the ICU for 18.6+/-3.6 days, were included in the study. Sixteen patients did not receive either drug (group A), five patients received dexamethasone (24 mg/day) for 4 days (group B), eight patients received dexamethasone (24 mg/day) for 4 days and atracurium (0.3-0.6 mg/kg/h) for 2.8+/-0.4 days (group C), whereas eight other non-hemiplegic ICU patients comprised the control group. MM was measured in cm by U/S and serum Albumin (ALB, g/l) at the first and the tenth ICU hospitalisation day. The corresponding differences (DeltaMM, DeltaALB) were compared between the four groups of patients. RESULTS:MM and ALB decreased significantly in all groups. DeltaMM was significantly higher in group C in comparison to all other groups, while DeltaMM was also higher in group B, when compared to the control and A groups. DeltaALB did not show significant inter-group differences. DeltaMM was significantly related to patients' age (r=0.41,P =0.001). CONCLUSIONS:Muscular atrophy of the ICU hemiplegic patients is significantly influenced by the synchronous treatment with muscle relaxants and corticosteroids at low doses and for short term. This myopathy should be taken into account for the better prognosis and the safer outcome of the patient and U/S is suitable for accurate and non-invasive monitoring of MM.
RCT Entities:
BACKGROUND AIMS: The present study investigates the influence of low-dose and short- term administration of corticosteroids and muscle relaxants on the muscular mass (MM) in hemiplegic ICUpatients, with the aid of ultrasonography (U/S). METHODS: Thirty-seven patients hospitalised in the ICU for 18.6+/-3.6 days, were included in the study. Sixteen patients did not receive either drug (group A), five patients received dexamethasone (24 mg/day) for 4 days (group B), eight patients received dexamethasone (24 mg/day) for 4 days and atracurium (0.3-0.6 mg/kg/h) for 2.8+/-0.4 days (group C), whereas eight other non-hemiplegic ICUpatients comprised the control group. MM was measured in cm by U/S and serum Albumin (ALB, g/l) at the first and the tenth ICU hospitalisation day. The corresponding differences (DeltaMM, DeltaALB) were compared between the four groups of patients. RESULTS: MM and ALB decreased significantly in all groups. DeltaMM was significantly higher in group C in comparison to all other groups, while DeltaMM was also higher in group B, when compared to the control and A groups. DeltaALB did not show significant inter-group differences. DeltaMM was significantly related to patients' age (r=0.41,P =0.001). CONCLUSIONS: Muscular atrophy of the ICU hemiplegicpatients is significantly influenced by the synchronous treatment with muscle relaxants and corticosteroids at low doses and for short term. This myopathy should be taken into account for the better prognosis and the safer outcome of the patient and U/S is suitable for accurate and non-invasive monitoring of MM.
Authors: Lee W Jones; Bebe Guill; Stephen T Keir; Karen Carter; Henry S Friedman; Darell D Bigner; David A Reardon Journal: Support Care Cancer Date: 2006-07-04 Impact factor: 3.603
Authors: David Beckwée; Lotte Cuypers; Nina Lefeber; Emma De Keersmaecker; Ellen Scheys; Wout Van Hees; Stany Perkisas; Sylvie De Raedt; Eric Kerckhofs; Ivan Bautmans; Eva Swinnen Journal: J Rehabil Med Date: 2022-10-04 Impact factor: 3.959
Authors: Monica Llano-Diez; Guillaume Renaud; Magnus Andersson; Humberto Gonzales Marrero; Nicola Cacciani; Henrik Engquist; Rebeca Corpeño; Konstantin Artemenko; Jonas Bergquist; Lars Larsson Journal: Crit Care Date: 2012-10-26 Impact factor: 9.097
Authors: Arabella Fischer; Matthias Spiegl; Klaus Altmann; Andreas Winkler; Anna Salamon; Michael Themessl-Huber; Mohamed Mouhieddine; Eva Maria Strasser; Arno Schiferer; Tatjana Paternostro-Sluga; Michael Hiesmayr Journal: Crit Care Date: 2016-01-29 Impact factor: 9.097
Authors: Esther Witteveen; Juultje Sommers; Luuk Wieske; Jonne Doorduin; Nens van Alfen; Marcus J Schultz; Ivo N van Schaik; Janneke Horn; Camiel Verhamme Journal: Ann Intensive Care Date: 2017-04-05 Impact factor: 6.925
Authors: P Formenti; M Umbrello; V Castagna; S Cenci; F Bichi; T Pozzi; M Bonifazi; S Coppola; D Chiumello Journal: J Crit Care Date: 2021-09-29 Impact factor: 3.425